Hemlibra

Active Ingredient(s): Emicizumab
FDA Approved: * November 16, 2017
Pharm Company: * GENENTECH INC
Category: Blood Clotting (Hemostasis)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Hemlibra Overview

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche).[1] A Phase I clinical trial found that it was well tolerated by healthy subjects.[2] In November 2017, it was approved in the United States for treatment of haemophilia A in those who had developed resistance to other treatments.[3] It was subsequently approved by the US FDA in April 2...

Read more Hemlibra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Emicizumab

Recent Hemlibra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Emicizumab
  • Injection: 105mg/0.7ml, 150mg, 30mg/ml, 60mg/0.4ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Hemlibra: (4 results)

Sorted by National Drug Code
  • 50242-920 Hemlibra 30 mg/ml Subcutaneous Injection, Solution by Genentech, Inc.
  • 50242-921 Hemlibra 150 mg/ml Subcutaneous Injection, Solution by Genentech, Inc.
  • 50242-922 Hemlibra 150 mg/ml Subcutaneous Injection, Solution by Genentech, Inc.
  • 50242-923 Hemlibra 150 mg/ml Subcutaneous Injection, Solution by Genentech, Inc.

Other drugs which contain Emicizumab or a similar ingredient: (1 result)